文章摘要
徐智超,唐海沁,张亚文,徐迎春,陈洁霞.血脂康与他汀类药物调脂效果对比及安全性分析[J].中国临床保健杂志,2017,20(1):28-32.
血脂康与他汀类药物调脂效果对比及安全性分析
Comparison of effectiveness and safety between Xuezhikang and statins for hyperlipidemia
投稿时间:2016-03-08  
DOI:10.3969/J.issn.1672-6790.2017.01.010
中文关键词: 降血脂药物  高脂血症  Meta分析
英文关键词: Hypolipidemic agents  Hyperlipidemias  Meta-Analysis〖FL
基金项目:国家中医药管理局国家中医临床研究基地业务建设科研专项课题(JDZX2015133)
作者单位E-mail
徐智超 安徽医科大学第一附属医院老年心血管科,合肥 230022 903276830@qq.com 
唐海沁 安徽医科大学第一附属医院老年心血管科,合肥 230022 tanghq898@sina.com 
张亚文 安徽医科大学第一附属医院老年心血管科,合肥 230022  
徐迎春 安徽医科大学第一附属医院老年心血管科,合肥 230022  
陈洁霞 安徽医科大学第一附属医院老年心血管科,合肥 230022  
摘要点击次数: 3153
全文下载次数: 1966
中文摘要:
      目的 评价血脂康与常见他汀类降脂药物对原发性高脂血症疗效。方法 计算机检索PubMed、Cochrane图书馆、万方医学数据库、维普中文科技期刊全文数据库,筛选关于中药血脂康与他汀类药物治疗原发性高脂血症随机对照实验。评价指标包括胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)。采用Revman5.3软件进行分析。结果 实验共纳入14篇文献,共计1150例患者,结果血脂康、他汀类药物均明显降低原发性高脂血症患者TC、TG、LDL-C,明显升高HDL-C,但Meta分析提示血脂康与他汀类药物对原发性高脂血症患者降低血TC、TG、LDL-C疗效差异无统计学意义[WMD=0.01mmol/L,95%CI:(-0.05~0.07)mmol/L,P>0.05;WMD=0.07 mmol/L,95%CI:(-0.26~0.41)mmol/L,P>0.05;WMD=0.13 mmol/L,95%CI: (-0.44~0.69)mmol/L,P>0.05],对升高患者血高密度脂蛋白疗效差异无统计学意义[WMD=0.13 mmol/L,95%CI:(-0.44~0.69)mmol/L,P>0.05]。结论 血脂康与他汀类药物均可降低原发性高脂血症患者血TC、TG、LDL-C,升高血HDL-C,两者疗效相当,血脂康致不良反应更少,安全性更高。
英文摘要:
      Objective To review systematically the effectiveness and safety of Xuezhikang and Statins for the patients with primary hyperlipidemia.Methods A literature research was performed in Cochrane library,PubMed,CNKI,WANFANG DATA and VIP full-text database to collect randomized controlled trials(RCT) about effectiveness of Xuezhikang and Statins for the patients with primary hyperlipidemia published from 1st June 2010 to 1st June 2015.The efficacy evaluation and safety were reviewed and a Meta-analysis was performed By using Revman 5.3 software.Results 1150 patients from 14 independent trials were included in this review.There were no homogeneity among most of the studies (P<0.05,I2>0.75),and the level of TC、TG、LDL-C in both Xuezhikang group and Statins group was lowered significantly,while the HDL-C level was elevated significantly.The results of Meta-analysis showed that there were no difference in the level of TC、TG、LDL-C and HDL-C between the two groups [WMD=0.01mmol/L,95%CI:(-0.05~0.07)mmol/L,P>0.05;WMD=0.07mmol/L,95%CI:(-0.26~0.41)mmol/L,P>0.05;WMD=0.13mmol/L,95%CI:(-0.44~0.69)mmol/L,P>0.05;WMD=0.13mmol/L,95%CI:(-0.44~0.69)mmol/L,P>0.05].Conclusion Both Xuezhikang and Statins show the effectiveness for the patients with primary hyperlipidemia,but Xuezhikang with less adverse events.
查看全文     
关闭
分享按钮